Results 161 to 170 of about 50,237 (216)

Predictive biomarkers for cetuximab-based rechallenge therapy in metastatic colorectal cancer: a pooled analysis of the CAVE and CAVE-2 GOIM studies. [PDF]

ESMO Gastrointest Oncol
Ciardiello D, Martini G, Pietrantonio F, Avallone A, Pisconti S, Santabarbara G, Latiano TP, Tortora G, Sartore-Bianchi A, Cremolini C, Messina M, Zampino MG, Foltran L, Pinto C, Zaniboni A, Antonuzzo L, Normanno N, Berardi R, Cogoni A, Lotesoriere C, Bordonaro R, Boscolo Bielo L, Curigliano G, Manca P, Leone AG, De Stefano A, Nisi C, Rossini D, Salvatore L, Maiello E, Siena S, Troiani T, De Vita F, Fazio N, Martinelli E, Ciardiello F, Napolitano S.   +36 more
europepmc   +1 more source

Cost-effectiveness analysis of triplet therapy of encorafenib, binimetinib, and cetuximab for treatment of metastatic BRAF V600E-mutated colorectal cancer in China. [PDF]

Front Pharmacol
Liu M, Liu T.
europepmc   +1 more source

Differential Tumor Response and Conversion Outcomes Associated with First-Line Biologic Strategies in Liver-Limited <i>RAS</i> Wild-Type Metastatic Colorectal Cancer. [PDF]

Oncol Res
Chiang SW, Chen MC, Lin CL, Huang YL, Chiang FF, Yang SF.   +5 more
europepmc   +1 more source

Efficacy and safety of cetuximab-irinotecan rechallenge versus regorafenib in ras wild-type metastatic colorectal cancer: a single-center exploratory randomized trial. [PDF]

BMC Cancer
Chen H, Jiang T, Wang H, Zheng J, Du B, Weng X, Yao N, Zhu Y, Liu Q, Lin F, Wang X, Lin X.   +11 more
europepmc   +1 more source

Outcomes and Prognostic Factors of Cetuximab-Based Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. [PDF]

J Clin Med
Dönmez Tekin M, Erdoğan AP, Şahbazlar M, Ekinci F.   +3 more
europepmc   +1 more source

The Impact of the G8 Score on Survival Outcomes in Patients With Head and Neck Cancer Undergoing Concurrent Radiotherapy With Cetuximab due to Contraindications With Cisplatin. [PDF]

Cancer Med
Kiraz E, Gündoğ M, Gönül R, Kara İ, Yüce İ, Çağlı S.   +5 more
europepmc   +1 more source

Trifunctional antibody fusion proteins for targeted co-delivery of 4-1BBL with IL-15 or IL-21 to enhance antitumor immune responses. [PDF]

Front Immunol
Möller AM, Baumann F, Pütter M, Xie M, Löffler AK, Müller D.   +5 more
europepmc   +1 more source

Economic evaluation of newly approved cetuximab biosimilars for first-line treatment of RAS/BRAF wild-type metastatic colorectal cancer in China. [PDF]

Front Oncol
Feng R, Huo L, Liang P, Li D, Cui R, Zheng Y, Lv Q.   +6 more
europepmc   +1 more source

Efficacy and safety of PD-1/PD-L1 inhibitors versus chemotherapy or cetuximab in the treatment of platinum-refractory recurrent or metastatic head and neck squamous cell carcinoma: a meta-analysis. [PDF]

Front Pharmacol
Chen Z, Zhong Z, Liang W, Feng Q, Wu M, Lin L, Huang G, Tang X, Quan J, Wei J, Qin J.   +10 more
europepmc   +1 more source

Cetuximab combination with cytokine induced killer cells effectively inhibit conjunctival squamous cell carcinoma in vitro. [PDF]

BMC Immunol
Aghaei H, Khakpour M, Dehghan S, Ghamari A, Shoae-Hassani A.   +4 more
europepmc   +1 more source